focus -WSS

focus

author：entertainment 2025-09-14 14:45:37 - browse：15

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Mass General, Mayo Clinic look to monetize custom

hotspot

WSS

Medicare drug price lawsuits could be good politics for Biden

Why a market frenzy over new weight loss drugs defies logic

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Study on Amgen’s bispecific immunotherapy produces positive data

To bolster infectious disease surveillance, genomics powerhouses team up

What causes osteoarthritis? Researchers study link to brain protein

hotspot

focus

Wikipedia

Virginia high school admissions case could be legal follow

STAT Summit: Meghan O’Rourke on making chronic illness visible

Cancer drug shortages should be causing more outrage

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Sports medicine is finally prioritizing gender equality

Why a market frenzy over new weight loss drugs defies logic

Peter Hotez and the public health issue of online harassment

Inaction leaves children at risk from dangerous chemotherapy drug

United colonoscopy coverage change 'may cost lives,' doctors say

The problems with dementia villages

explore

Smaller biotechs seek to piggyback on weight loss drug boom

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

High breast density mammograms need follow

The problems with dementia villages

High breast density mammograms need follow

Roivant's CEO is a star, but biotech's black hole persists

hotspot

leisure time

leisure time

hotspot